BMS/Bain $300m Venture Emerges As Beeline With Lead Asset Nearing Pivotal Stage

Inflammation And Immunology Drugs Advancing In Clinic

 
• By Mandy Jackson
  
Glowing Blue Startup Business Launch
Beeline launches with programs in preclinical through Phase IIb (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Immune Disorders

More from Disease